273 related articles for article (PubMed ID: 2321777)
1. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
Allen GC; Rosenberg H; Fletcher JE
Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
[TBL] [Abstract][Full Text] [Related]
2. Malignant hyperthermia.
Halliday NJ
J Craniofac Surg; 2003 Sep; 14(5):800-2. PubMed ID: 14501352
[TBL] [Abstract][Full Text] [Related]
3. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE
Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468
[TBL] [Abstract][Full Text] [Related]
4. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
Sato N; Brum JM; Mitsumoto H; DeBoer GE
Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
[TBL] [Abstract][Full Text] [Related]
5. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
7. Management of otolaryngic patients susceptible to malignant hyperthermia without dantrolene.
Derkay CS; Grundfast KM
Otolaryngol Head Neck Surg; 1991 Nov; 105(5):680-6. PubMed ID: 1754251
[TBL] [Abstract][Full Text] [Related]
8. [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome].
Bello N; Adnet P; Saulnier F; Lestavel P; Adnet-Bonte C; Reyford H; Etchrivi T; Tavernier B; Krivosic-Horber R
Ann Fr Anesth Reanim; 1994; 13(5):663-8. PubMed ID: 7733515
[TBL] [Abstract][Full Text] [Related]
9. Masseter muscle rigidity and malignant hyperthermia susceptibility.
Rosenberg H; Fletcher JE
Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
[TBL] [Abstract][Full Text] [Related]
10. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
Riazi S; Larach MG; Hu C; Wijeysundera D; Massey C; Kraeva N
Anesth Analg; 2014 Feb; 118(2):381-387. PubMed ID: 23842196
[TBL] [Abstract][Full Text] [Related]
11. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
[TBL] [Abstract][Full Text] [Related]
12. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
Allen GC; Larach MG; Kunselman AR
Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
[TBL] [Abstract][Full Text] [Related]
13. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
[TBL] [Abstract][Full Text] [Related]
15. Malignant hyperthermia.
Rosenberg H; Davis M; James D; Pollock N; Stowell K
Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
[TBL] [Abstract][Full Text] [Related]
16. Malignant hyperthermia in the oral and maxillofacial surgery patient: an update.
Patil PM
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Sep; 112(3):e1-7. PubMed ID: 21827956
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
[TBL] [Abstract][Full Text] [Related]
18. Malignant hyperthermia susceptibility in a patient with mitochondrial disorder.
Finsterer J; Michalek-Sauberer A; Höftberger R
Metab Brain Dis; 2009 Sep; 24(3):501-6. PubMed ID: 19714456
[TBL] [Abstract][Full Text] [Related]
19. Halothane-caffeine contracture testing in neuromuscular diseases.
Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
